Clinical Trial Update: Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eribulin mesylate in patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Eribulin mesylate (Halaven) (eribulin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-12-10